Table 1

Characteristics of the study population

The age range, location, and disease status of HER-2/neu-overexpressing cancers present in the patients evaluated are shown.

DiagnosisDisease statusTotal no. of patients (n = 32)
Complete responseStable diseaseProgressive disease
Stage III9NAaNA9
Stage IV511117
Stage III112
Stage IV112
NSC lung12
Stage III11
Stage IV11
Age, median years (range)51 (34–86)
  • a NA, not applicable; NSC, non-small cell.